Serotonin Toxicity Association with Concomitant Antidepressants and Rasagiline Treatment: Retrospective Study (STACCATO)
Identifieur interne : 000B85 ( Main/Exploration ); précédent : 000B84; suivant : 000B86Serotonin Toxicity Association with Concomitant Antidepressants and Rasagiline Treatment: Retrospective Study (STACCATO)
Auteurs : Michel Panisset [Canada] ; Jack J. Chen [États-Unis] ; Sean H. Rhyee [États-Unis] ; Jill Conner [États-Unis] ; Julie Mathena [États-Unis]Source :
- Pharmacotherapy [ 0277-0008 ] ; 2014.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
BACKGROUND The serotonin toxicity syndrome (STS) is a potential risk with concurrent use of the monoamine oxidase type-B inhibitor rasagiline and antidepressants. OBJECTIVE To assess systematically the occurrence of STS in patients with Parkinson disease (PD) treated with rasagiline plus antidepressants (R+ATD), rasagiline without antidepressants (R), or antidepressants plus anti-PD dopaminergic medications (ATD) other than either rasagiline or selegiline. METHODS A phase IV multicenter retrospective cohort study was conducted of patients with PD who began receiving R+ATD, R, or ATD between September 1, 2006, and December 31, 2008. Medical records were reviewed for patient demographics, treatment details, and hospitalizations/emergency department (ED) visits. An adjudication committee independently reviewed records to verify case ascertainment and used the Hunter Serotonin Toxicity Criteria for case definition. Outcome variables were analyzed by descriptive statistics. RESULTS A total of 1504 patients with PD (471 with R+ATD; 511 with R; and 525 with ATD) were enrolled from 37 sites. In the R+ATD and ATD groups, selective serotonin reuptake inhibitors (SSRIs) were most frequently used (74.5% and 77%, respectively). In the R+ATD and ATD groups, mean duration of antidepressant use (tricyclic, SSRI, and other) were 50.5-53.5 weeks and 51.7- 80.9 weeks, respectively. Overall, 195 patients (13%) from all three groups had one or more hospitalization/ED visits. No cases of STS were identified in any group. CONCLUSIONS In this large multicenter retrospective cohort study, concurrent administration of R+ATD was not associated with STS. The findings of this phase IV study expand the drug interaction and pharmacovigilance safety awareness for the use of antidepressants in patients with PD.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000001
- to stream PascalFrancis, to step Corpus: 000004
- to stream PascalFrancis, to step Curation: 000C15
- to stream PascalFrancis, to step Checkpoint: 000005
- to stream Main, to step Merge: 000B90
- to stream Main, to step Curation: 000B85
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Serotonin Toxicity Association with Concomitant Antidepressants and Rasagiline Treatment: Retrospective Study (STACCATO)</title><author><name sortKey="Panisset, Michel" sort="Panisset, Michel" uniqKey="Panisset M" first="Michel" last="Panisset">Michel Panisset</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Hôpital Notre-Dame du CHUM</s1><s2>Montréal, Québec</s2><s3>CAN</s3><sZ>1 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Hôpital Notre-Dame du CHUM</wicri:noRegion></affiliation></author><author><name sortKey="Chen, Jack J" sort="Chen, Jack J" uniqKey="Chen J" first="Jack J." last="Chen">Jack J. Chen</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Loma Linda University</s1><s2>Loma Linda, California</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Rhyee, Sean H" sort="Rhyee, Sean H" uniqKey="Rhyee S" first="Sean H." last="Rhyee">Sean H. Rhyee</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>University of Massachusetts Medical School</s1><s2>Worcester, Massachusetts</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Conner, Jill" sort="Conner, Jill" uniqKey="Conner J" first="Jill" last="Conner">Jill Conner</name><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Teva Neuroscience, Inc.</s1><s2>Kansas City, Missouri</s2><s3>USA</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Missouri (État)</region></placeName></affiliation></author><author><name sortKey="Mathena, Julie" sort="Mathena, Julie" uniqKey="Mathena J" first="Julie" last="Mathena">Julie Mathena</name><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Teva Neuroscience, Inc.</s1><s2>Kansas City, Missouri</s2><s3>USA</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Missouri (État)</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">15-0030957</idno><date when="2014">2014</date><idno type="stanalyst">PASCAL 15-0030957 INIST</idno><idno type="RBID">Pascal:15-0030957</idno><idno type="wicri:Area/PascalFrancis/Corpus">000001</idno><idno type="stanalyst">FRANCIS 15-0030957 INIST</idno><idno type="wicri:Area/PascalFrancis/Corpus">000004</idno><idno type="wicri:Area/PascalFrancis/Curation">000C15</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000005</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000005</idno><idno type="wicri:doubleKey">0277-0008:2014:Panisset M:serotonin:toxicity:association</idno><idno type="wicri:Area/Main/Merge">000B90</idno><idno type="wicri:Area/Main/Curation">000B85</idno><idno type="wicri:Area/Main/Exploration">000B85</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Serotonin Toxicity Association with Concomitant Antidepressants and Rasagiline Treatment: Retrospective Study (STACCATO)</title><author><name sortKey="Panisset, Michel" sort="Panisset, Michel" uniqKey="Panisset M" first="Michel" last="Panisset">Michel Panisset</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Hôpital Notre-Dame du CHUM</s1><s2>Montréal, Québec</s2><s3>CAN</s3><sZ>1 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Hôpital Notre-Dame du CHUM</wicri:noRegion></affiliation></author><author><name sortKey="Chen, Jack J" sort="Chen, Jack J" uniqKey="Chen J" first="Jack J." last="Chen">Jack J. Chen</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Loma Linda University</s1><s2>Loma Linda, California</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Rhyee, Sean H" sort="Rhyee, Sean H" uniqKey="Rhyee S" first="Sean H." last="Rhyee">Sean H. Rhyee</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>University of Massachusetts Medical School</s1><s2>Worcester, Massachusetts</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Conner, Jill" sort="Conner, Jill" uniqKey="Conner J" first="Jill" last="Conner">Jill Conner</name><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Teva Neuroscience, Inc.</s1><s2>Kansas City, Missouri</s2><s3>USA</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Missouri (État)</region></placeName></affiliation></author><author><name sortKey="Mathena, Julie" sort="Mathena, Julie" uniqKey="Mathena J" first="Julie" last="Mathena">Julie Mathena</name><affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Teva Neuroscience, Inc.</s1><s2>Kansas City, Missouri</s2><s3>USA</s3><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Missouri (État)</region></placeName></affiliation></author></analytic><series><title level="j" type="main">Pharmacotherapy</title><title level="j" type="abbreviated">Pharmacotherapy</title><idno type="ISSN">0277-0008</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Pharmacotherapy</title><title level="j" type="abbreviated">Pharmacotherapy</title><idno type="ISSN">0277-0008</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antidepressant agent</term><term>Antiparkinson agent</term><term>Depression</term><term>Parkinson disease</term><term>Parkinsonism</term><term>Psychotropic</term><term>Rasagiline</term><term>Retrospective</term><term>Serotonin</term><term>Toxicity</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Sérotonine</term><term>Toxicité</term><term>Antidépresseur</term><term>Rasagiline</term><term>Traitement</term><term>Rétrospective</term><term>Etat dépressif</term><term>Maladie de Parkinson</term><term>Parkinsonisme</term><term>Psychotrope</term><term>Antiparkinsonien</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">BACKGROUND The serotonin toxicity syndrome (STS) is a potential risk with concurrent use of the monoamine oxidase type-B inhibitor rasagiline and antidepressants. OBJECTIVE To assess systematically the occurrence of STS in patients with Parkinson disease (PD) treated with rasagiline plus antidepressants (R+ATD), rasagiline without antidepressants (R), or antidepressants plus anti-PD dopaminergic medications (ATD) other than either rasagiline or selegiline. METHODS A phase IV multicenter retrospective cohort study was conducted of patients with PD who began receiving R+ATD, R, or ATD between September 1, 2006, and December 31, 2008. Medical records were reviewed for patient demographics, treatment details, and hospitalizations/emergency department (ED) visits. An adjudication committee independently reviewed records to verify case ascertainment and used the Hunter Serotonin Toxicity Criteria for case definition. Outcome variables were analyzed by descriptive statistics. RESULTS A total of 1504 patients with PD (471 with R+ATD; 511 with R; and 525 with ATD) were enrolled from 37 sites. In the R+ATD and ATD groups, selective serotonin reuptake inhibitors (SSRIs) were most frequently used (74.5% and 77%, respectively). In the R+ATD and ATD groups, mean duration of antidepressant use (tricyclic, SSRI, and other) were 50.5-53.5 weeks and 51.7- 80.9 weeks, respectively. Overall, 195 patients (13%) from all three groups had one or more hospitalization/ED visits. No cases of STS were identified in any group. CONCLUSIONS In this large multicenter retrospective cohort study, concurrent administration of R+ATD was not associated with STS. The findings of this phase IV study expand the drug interaction and pharmacovigilance safety awareness for the use of antidepressants in patients with PD.</div></front></TEI><affiliations><list><country><li>Canada</li><li>États-Unis</li></country><region><li>Californie</li><li>Massachusetts</li><li>Missouri (État)</li></region></list><tree><country name="Canada"><noRegion><name sortKey="Panisset, Michel" sort="Panisset, Michel" uniqKey="Panisset M" first="Michel" last="Panisset">Michel Panisset</name></noRegion></country><country name="États-Unis"><region name="Californie"><name sortKey="Chen, Jack J" sort="Chen, Jack J" uniqKey="Chen J" first="Jack J." last="Chen">Jack J. Chen</name></region><name sortKey="Conner, Jill" sort="Conner, Jill" uniqKey="Conner J" first="Jill" last="Conner">Jill Conner</name><name sortKey="Mathena, Julie" sort="Mathena, Julie" uniqKey="Mathena J" first="Julie" last="Mathena">Julie Mathena</name><name sortKey="Rhyee, Sean H" sort="Rhyee, Sean H" uniqKey="Rhyee S" first="Sean H." last="Rhyee">Sean H. Rhyee</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B85 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000B85 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:15-0030957
|texte= Serotonin Toxicity Association with Concomitant Antidepressants and Rasagiline Treatment: Retrospective Study (STACCATO)
}}
| This area was generated with Dilib version V0.6.29. |  |